Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism


Author index

Page Path
Beom Seok Kim  (Kim BS) 2 Articles
Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes
Eugene Han, Gyuri Kim, Ji-Yeon Lee, Yong-ho Lee, Beom Seok Kim, Byung-Wan Lee, Bong-Soo Cha, Eun Seok Kang
Endocrinol Metab. 2017;32(2):274-280.   Published online June 23, 2017
  • 5,187 View
  • 174 Download
  • 8 Web of Science
  • 8 Crossref
AbstractAbstract PDFPubReader   

Although the beneficial effects of statin treatment in dyslipidemia and atherosclerosis have been well studied, there is limited information regarding the renal effects of statins in diabetic nephropathy. We aimed to investigate whether, and which, statins affected renal function in Asian patients with diabetes.


We enrolled 484 patients with diabetes who received statin treatment for more than 12 months. We included patients treated with moderate-intensity dose statin treatment (atorvastatin 10 to 20 mg/day or rosuvastatin 5 to 10 mg/day). The primary outcome was a change in estimated glomerular filtration rate (eGFR) during the 12-month statin treatment, and rapid renal decline was defined as a >3% reduction in eGFR in a 1-year period.


In both statin treatment groups, patients showed improved serum lipid levels and significantly reduced eGFRs (from 80.3 to 78.8 mL/min/1.73 m2 for atorvastatin [P=0.012], from 79.1 to 76.1 mL/min/1.73 m2 for rosuvastatin [P=0.001]). A more rapid eGFR decline was observed in the rosuvastatin group than in the atorvastatin group (48.7% vs. 38.6%, P=0.029). Multiple logistic regression analyses demonstrated more rapid renal function loss in the rosuvastatin group than in the atorvastatin group after adjustment for other confounding factors (odds ratio, 1.60; 95% confidence interval, 1.06 to 2.42).


These results suggest that a moderate-intensity dose of atorvastatin has fewer detrimental effects on renal function than that of rosuvastatin.


Citations to this article as recorded by  
  • Efficacy and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe in patients with dyslipidemia and hypertension: A randomized, double‐blind, multicenter, therapeutic confirmatory, phase III clinical trial
    Chan Joo Lee, Woong Chol Kang, Sang Hyun Ihm, Il Suk Sohn, Jong Shin Woo, Jin Won Kim, Soon Jun Hong, Jung Hyun Choi, Jung‐Won Suh, Jae‐Bin Seo, Joon‐Hyung Doh, Jung‐Woo Son, Jae‐Hyeong Park, Ju‐Hee Lee, Young Joon Hong, Jung Ho Heo, Jinho Shin, Seok‐Min
    The Journal of Clinical Hypertension.2024; 26(3): 262.     CrossRef
  • Anti-hyperglycemic, anti-hyperlipidemic, and anti-inflammatory effect of the drug Guggulutiktaka ghrita on high-fat diet-induced obese rats
    Samreen M. Sheik, Pugazhandhi Bakthavatchalam, Revathi P. Shenoy, Basavaraj S. Hadapad, Deepak Nayak M, Monalisa Biswas, Varashree Bolar Suryakanth
    Journal of Ayurveda and Integrative Medicine.2022; 13(3): 100583.     CrossRef
  • The challenge of reducing residual cardiovascular risk in patients with chronic kidney disease
    Stefan Mark Nidorf
    European Heart Journal.2022; 43(46): 4845.     CrossRef
  • Diabetic Kidney Disease in Older People with Type 2 Diabetes Mellitus: Improving Prevention and Treatment Options
    Ahmed H. Abdelhafiz
    Drugs & Aging.2020; 37(8): 567.     CrossRef
  • Intracellular Mechanism of Rosuvastatin-Induced Decrease in Mature hERG Protein Expression on Membrane
    Pan-Feng Feng, Bo Zhang, Lei Zhao, Qing Fang, Yan Liu, Jun-Nan Wang, Xue-Qi Xu, Hui Xue, Yang Li, Cai-Chuan Yan, Xin Zhao, Bao-Xin Li
    Molecular Pharmaceutics.2019; 16(4): 1477.     CrossRef
  • The problem of safety of lipid-lowering therapy
    M V. Zykov
    Kardiologiia.2019; 59(5S): 13.     CrossRef
  • Regional evidence and international recommendations to guide lipid management in Asian patients with type 2 diabetes with special reference to renal dysfunction
    Titus WL Lau, Kevin E.K. Tan, Jason C.J. Choo, Tsun‐Gun Ng, Subramaniam Tavintharan, Juliana C.N. Chan
    Journal of Diabetes.2018; 10(3): 200.     CrossRef
  • Lipids: a personal view of the past decade
    Niki Katsiki, Dimitri P Mikhailidis
    Hormones.2018; 17(4): 461.     CrossRef
Close layer
A Case of Autoimmune Hypoglycemia due to Insulin Antibody in Patient with End Stage Renal Disease.
Ji Ye Jung, Eun Seok Kang, Beom Seok Kim, Sung Wan Chun, Yumie Rhee, Chul Woo Ahn, Bong Soo Cha, Eun Jig Lee, Sung Kil Lim, Hyun Chul Lee
J Korean Endocr Soc. 2006;21(6):536-541.   Published online December 1, 2006
  • 1,626 View
  • 17 Download
AbstractAbstract PDF
Fasting hypoglycemia results from several mechanisms. Autoimmune hypoglycemia is one of the rare causes of hypoglycemia, and characterized by hyperinsulinemia, fasting hypoglycemia and the presence of autoantibodies to insulin or insulin receptor. We report here on a 64-year-old male patient with autoimmune hypoglycemia with end stage renal disease. He had no history of diabetes or insulin use. He had experienced several severe hypoglycemic events. The serum C-peptide level was 7.48 ng/mL and the insulin concentration was 115.4 micro U/mL when the fasting plasma glucose level was 88 mg/dL. The insulin to glucose ratio was 5.42, which suggested the presence of insulinoma. Yet the radiologic studies, including magnetic resonance cholangiopancreatography, endoscopic ultrasonography and selective calcium stimulated venous sampling revealed no evidence of insulinoma. The insulin autoantibody level was 62 micro U/mL. Therefore, we could diagnosis the autoimmune hypoglycemia. The hypoglycemia was treated with prednisolone and the patient recovered from this. His insulin level decreased to 21.11 micro U/mL and the insulin autoantibody level decreased to 34 micro U/mL. Hypoglycemia in the hemodialysis patients is not uncommon. One should bear in mind autoimmune hypoglycemia as one of the causes of hypoglycemia in patients with no history of diabetes.
Close layer

Endocrinol Metab : Endocrinology and Metabolism